Type 2 diabetes

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, August 11, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2023 and provided business updates.

Key Points: 
  • “These results add to the growing body of evidence supporting the ongoing clinical development of EFX and its potential as a transformative NASH therapy.
  • Akero remains on track to report Week 36 results of the Phase 2b SYMMETRY main study in adult patients with cirrhotic NASH (F4, compensated) in the fourth quarter of 2023.
  • Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended June 30, 2023 were $658.9 million.
  • Total operating expenses were $35.6 million for the three-month period ended June 30, 2023, compared to $27.6 million for the comparable period in 2022.

Washington Research Foundation awards $100,000 to Pacific Northwest Research Institute in honor of David J. Galas, Ph.D.

Retrieved on: 
Thursday, August 10, 2023

SEATTLE, Aug. 10, 2023 /PRNewswire-PRWeb/ -- Washington Research Foundation (WRF) has awarded a $100,000 grant to Pacific Northwest Research Institute (PNRI) in honor of David J. Galas, Ph.D., who helped to create the WRF Postdoctoral Fellowship program in 2017 and served on the WRF board of directors from 2010 until his death in May. The grant will support the continuation of work begun by Galas and his colleague Lisa Stubbs, Ph.D., investigating the genetic links between stress and a range of health disorders.

Key Points: 
  • He was a leader in the Human Genome Project and a key contributor to the technology that enabled one of the earliest rapid tests for COVID-19.
  • Galas and his team focused on developing and applying innovative mathematical methods, providing new computational tools to seek out and validate genetic interactions significant to this research.
  • Brooks Simpson, WRF's board chair, said, "David was an incredible board member and mentor to all of us.
  • That will always remain a hallmark of our contributions to the research engines in the region."

Marius Pharmaceuticals Partners with Smartway to Design and Manage the global Early Access Program for KYZATREX™ (testosterone undecanoate)

Retrieved on: 
Thursday, August 10, 2023

RALEIGH, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals (Marius) and Smartway Pharmaceuticals (Smartway) are pleased to announce their strategic partnership, aimed at addressing the pressing global issue of hypogonadism through the launch of a comprehensive Early Access Program for KYZATREX™ (testosterone undecanoate).

Key Points: 
  • RALEIGH, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals (Marius) and Smartway Pharmaceuticals (Smartway) are pleased to announce their strategic partnership, aimed at addressing the pressing global issue of hypogonadism through the launch of a comprehensive Early Access Program for KYZATREX™ (testosterone undecanoate).
  • Smartway Pharmaceuticals, a specialist in the provision of early access, compassionate use, and named patient supply of new therapeutics, is appointed the exclusive Early Access Provider for KYZATREX™ in all countries outside of the USA.
  • Smartway has the capability to provide access to KYZATREX™ on a global basis while meeting the strict regulatory standards.
  • Smartway matches our desire to help patients and has the expertise combined with a global network to get KYZATREX™ to patients.

Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”

Retrieved on: 
Thursday, August 10, 2023

“Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • “To see Recce making a difference for patients in such great medical need is a significant sign of new hope in the fight against drug-resistant superbugs.
  • Upon applying R327G, the initial redness and swelling had minimized after seven days, with the wound healing and drying up.
  • Surgical intervention was averted, such as limb amputation, which is common in patients with diabetes.

DarioHealth Reports Second Quarter 2023 Financial and Operating Results

Retrieved on: 
Thursday, August 10, 2023

"Of note, we increased our gross profit margin to 33.7% in the second quarter of 2023 compared to 18.4% in the second quarter of 2022.

Key Points: 
  • "Of note, we increased our gross profit margin to 33.7% in the second quarter of 2023 compared to 18.4% in the second quarter of 2022.
  • Financial Results for the Three Months Ended June 30, 2023:
    Revenues for the second quarter ended June 30, 2023, were $6.15 million, a 0.5% decrease from $6.18 million for the second quarter ended June 30, 2022, and a decrease of 13% from $7.07 million for the first quarter of 2023.
  • Total operating expenses for the second quarter of 2023 were $16.1 million, compared with $18.5 million for the second quarter of 2022, and $15.6 million for the first quarter of 2023, a decrease of $2.4 million, or 13%, compared to the second quarter of 2022, and an increase of $0.5 million, or 3.3%, compared to the first quarter of 2023.
  • Operating loss excluding stock-based compensation, amortization of acquisition related expenses earn-out measurement and depreciation for the second quarter of 2023 was $7.5 million compared to $11.1 million for the second quarter of 2022, and $6.3 million for the first quarter of 2023.

Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, August 9, 2023

(NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the second quarter 2023 and provided an update on progress towards achieving key corporate milestones.

Key Points: 
  • (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the second quarter 2023 and provided an update on progress towards achieving key corporate milestones.
  • Completed Multiple Financing Transactions: In April 2023, Better Therapeutics announced a private placement financing for gross proceeds of approximately $6.5 million before deducting offering expenses payable by the Company.
  • In July 2023, Better Therapeutics announced the completion of an additional $6.7 million in net proceeds from multiple equity transactions.
  • Better Therapeutics periodically provides other information for investors on its corporate website, http://www.bettertx.com , and its investor relations website, https://investors.bettertx.com .

Can physical activity boost our resilience to rising temperatures?

Retrieved on: 
Tuesday, August 8, 2023

The increased frequency, duration and intensity of heat waves is one of the undeniable signs that climate change is well underway.

Key Points: 
  • The increased frequency, duration and intensity of heat waves is one of the undeniable signs that climate change is well underway.
  • As researchers in physical activity science and environmental physiology, we are assessing how adopting an active lifestyle can make us better equipped to cope with rising global temperatures.

How can the human body combat heat?

    • When exposed to heat, the body deploys several responses to try to dissipate it.
    • So it’s not surprising that any factor that affects these responses can alter the body’s ability to react adequately to heat exposure.

Who are the most vulnerable groups?

    • Although heat affects us all, evidence shows that certain groups of people are more sensitive to it, which increases their vulnerability.
    • This finding can be explained by the fact that several of these conditions are associated with two physiological responses:


    Together, these two conditions increase the likelihood that the stress placed on the body will reach and exceed the body’s physiological potential, increasing the risk of developing heat-related health problems.

How can regular physical activity improve resilience to heat?


    Interestingly, of the many risk factors for developing heat-related health problems, several can be avoided by adopting a healthy, active lifestyle. In fact, doing regular physical activity throughout one’s life could mean being better equipped to cope with rising global temperatures:
    • Physical activity could therefore make an important contribution to our ability to adapt to rising global temperatures, increasing our individual and community resilience.
    • It is also well established that people who engage in intense to moderate physical activity during heat episodes are at greater risk of developing heat-related health problems (agricultural workers, construction workers, restaurant workers, etc.

Is the next generation sufficiently equipped to meet this challenge?

    • Currently, more than nine out of 10 young people do not meet Canada’s 24-hour exercise guidelines.
    • Such trends suggest that today’s young people may be less and less equipped to tolerate heat, while they will be increasingly exposed to it.
    • Maintaining regular physical activity and adequate fitness throughout their lives could make young people better equipped to meet these challenges.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023

Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration

Key Points: 
  • Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration
    NASH disease education and market development activities expand to support potential first-to-market launch in the U.S.
    CONSHOHOCKEN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports second quarter 2023 financial results.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “The recent submission of the resmetirom NDA represents an important milestone for Madrigal and the NASH community.
  • Madrigal presented the Phase 3 MAESTRO-NASH primary results during the opening general session of the EASL Congress™.
  • Financial Results for the Six Months Ended June 30, 2023
    As of June 30, 2023, Madrigal had cash, cash equivalents and marketable securities of $298.4 million, compared to $358.8 million at December 31, 2022.

Ochsner Digital Medicine Partners with Hawaii-Based AlohaCare

Retrieved on: 
Monday, August 7, 2023

NEW ORLEANS, La., Aug. 7, 2023 /PRNewswire/ -- Ochsner Digital Medicine will partner with Hawaii-based health plan AlohaCare to provide digital medicine services to its members.

Key Points: 
  • NEW ORLEANS, La., Aug. 7, 2023 /PRNewswire/ -- Ochsner Digital Medicine will partner with Hawaii-based health plan AlohaCare to provide digital medicine services to its members.
  • Ochsner Digital Medicine to partner with Hawaii-based health plan AlohaCare to provide digital medicine services.
  • Through this partnership, Ochsner Digital Medicine will offer AlohaCare members who have been diagnosed with Hypertension and Type 2 diabetes remote programs designed to manage and control their conditions.
  • Ochsner Health was among the earliest innovators in remote patient management and is recognized as a leader in digital medicine.

Is red meat bad for you? And does it make a difference if it's a processed burger or a lean steak?

Retrieved on: 
Sunday, August 6, 2023

Yet research shows regularly eating red meat can increase your risk of developing type 2 diabetes, heart disease and certain cancers.

Key Points: 
  • Yet research shows regularly eating red meat can increase your risk of developing type 2 diabetes, heart disease and certain cancers.
  • And how much red meat should we really be eating?

Types of red meat

    • First of all, it’s good to clarify that red meat refers to all mammalian muscle meat.
    • Then we can distinguish red meat types by how the animal has been raised and how the meat is processed.
    • This means grass-fed meat tends to have higher levels of unsaturated fats than conventional meat, and is why some research suggests it’s healthier.

What is the nutritional value of red meat?

    • Red meat contains many nutrients that are important for health, including protein, vitamin B12, iron and zinc.
    • Red meat is a good source of iron and zinc as they are more easily absorbed by the body from meat than from plant foods.
    • Red meat is often high in saturated fats, but this can range widely from less than 1% to over 25% depending on the cut and whether it’s trimmed of fat or not.

Is red meat bad for your health? And does the type matter?

    • It’s widely reported eating too much red meat is bad for your health, because it can increase your risk of heart disease, type 2 diabetes and some cancers.
    • But most of the evidence for this comes from observational studies, which cannot determine whether red meat intake actually causes the condition.
    • Cancer Leading international organisations have declared there’s strong evidence consumption of red and processed meat increases the risk of colorectal cancer.
    • Read more:
      Yes, we still need to cut down on red and processed meat

How much red meat should you eat?

    • For heart health specifically, the national Heart Foundation recommends eating less than 350g of cooked, unprocessed red meat per week (or less than 50g a day).
    • To optimise both human nutrition and planetary health, the EAT-Lancet commission recommends consuming no more than 98g a week of red meat and very low intakes of processed meat.

So what does all of this mean for your diet?

    • Where possible, opt for unprocessed or lean cuts, and try to grill less and roast more.
    • Read more:
      How to get the nutrients you need without eating as much red meat